T-DXd with ramucirumab for HER2-low stomach and GEJ cancer
Part of Cancer, Digestive system clinical trials.
This trial studies T-DXd given with ramucirumab to treat stomach (gastric) or stomach–esophagus junction (GEJ) cancer that has spread or is locally advanced and is “HER2-low.” It’s mainly to test safety and early effectiveness in people whose cancer continued after first-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 19 years or older and can sign informed consent.
- Your cancer is metastatic or locally advanced HER2-low gastric or GEJ adenocarcinoma (HER2 is low on lab testing).
- Your cancer got worse after your first palliative treatment (some past chemo counts as first-line if it came back within 6 months).
- You can have scans/assessments showing measurable or evaluable disease, and your overall function score is ECOG 0–1.
- Your blood counts and organ tests (heart, kidneys, liver, etc.) must meet required minimums, including heart strength (LVEF ≥ 50%).
- You must be able to wait a set time after prior surgery, radiation, or cancer treatment before starting this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
This trial tests a new approach for stomach cancer that has spread to nearby tissues but not to other organs. You would get a short course of radiation, followed by a combination of targeted therapy (Disitamab Vedotin), chemotherapy (S-1), and immunotherapy (Sintilimab) before surgery to shrink the tumor and improve outcomes.
This trial tests a drug called T-DXd in people with advanced non-squamous lung cancer that has a specific HER2 gene change (mutation) and has spread to the brain but isn't causing symptoms. The goal is to see if the drug can shrink tumors and help control the cancer.
This study looks at how well the drug trastuzumab deruxtecan (T-DXd) works and how safe it is in people with advanced HER2-positive stomach or gastroesophageal junction cancer in China. It may be an option if you have already had other treatments.
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
This study tests a new combination treatment for metastatic breast cancer that is HER2-positive or HER2-low and has stopped responding to T-DXd. The combination includes T-DXd plus a new drug that targets RAGE. The goal is to see if this combination can shrink tumors or slow their growth.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.